Takeda officer files initial Form 3 statement

Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer.

Accepted by SEC EDGAR 05/05/2026 - 06:31 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer. The filing does not report any insider transactions or holdings; it simply establishes her status as a reporting person for future disclosures.

Key Terms

Form 3, Chief Comm. & Gov. Officer, reportingPersons

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Comm. & Gov. Officer financial

""officer_title": "Chief Comm. & Gov. Officer""

reportingPersons regulatory

""reportingPersons": ["

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for TAK executive Jennifer Marie Smoter show?

The Form 3 shows that Jennifer Marie Smoter, Takeda’s Chief Communications & Government Officer, is now a reporting person. It does not list any current transactions or share holdings, serving mainly as an initial beneficial ownership registration.

Did Jennifer Marie Smoter buy or sell TAK shares in this Form 3 filing?

No, this Form 3 does not report any purchases or sales of TAK shares by Jennifer Marie Smoter. The transaction section is empty, indicating no insider trading activity is being disclosed in this particular filing.

What is Jennifer Marie Smoter’s role at Takeda Pharmaceutical (TAK)?

Jennifer Marie Smoter is identified as Takeda’s Chief Communications & Government Officer in the Form 3. This officer role makes her subject to insider reporting requirements for future transactions involving Takeda securities under U.S. securities regulations.

Why is Takeda Pharmaceutical (TAK) filing a Form 3 for this officer?

Takeda filed this Form 3 to register Jennifer Marie Smoter as an insider subject to reporting rules. Form 3 is the initial statement of beneficial ownership that precedes later Form 4 or Form 5 filings showing any future trades or equity awards.

Does the TAK Form 3 disclose any derivative securities for the officer?

No, the Form 3 data for Jennifer Marie Smoter shows an empty derivative summary. This means no options, warrants, or other derivative positions are reported for her in this particular filing with the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Smoter Jennifer Marie

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/27/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Comm. & Gov. Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Ex. 24, Power of Attorney

No securities are beneficially owned.

	/s/ Max Heuer, by power of attorney, for Jennifer Smoter	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)